Illumina Inc. (ILMN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Illumina ( ILMN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.8%. By the end of trading, Illumina rose $1.09 (1.4%) to $78.37 on light volume. Throughout the day, 880,817 shares of Illumina exchanged hands as compared to its average daily volume of 1,338,000 shares. The stock ranged in a price between $77.00-$78.95 after having opened the day at $77.35 as compared to the previous trading day's close of $77.28. Other companies within the Drugs industry that increased today were: Compugen ( CGEN), up 44.5%, Inovio Pharmaceuticals ( INO), up 44.2%, Aastrom Biosciences ( ASTM), up 31.1% and Onconova Therapeutics ( ONTX), up 23.8%.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $9.9 billion and is part of the health care sector. Shares are up 42.9% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 40.0%, Prima Biomed ( PBMD), down 8.8%, Prosensa Holding N.V ( RNA), down 8.2% and Chembio Diagnostics ( CEMI), down 7.5% , were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.